A Phase 1/2 interventional study of Carboplatin and Placebo in Small Cell Lung Cancer, sponsored by G1 Therapeutics, Inc.. Completed at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-21.
Sponsored by G1 Therapeutics, Inc. (part of Pharmacosmos A/S) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 163rd largest by enrollment of the 550 interventional ones that give a count, is one of 18 that started in 2015, is one of 113 in phase 1/2, and was the 297th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:
Misty Shields · Sites in United States
Ages 18+
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Jazz Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
629 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 295 · Phase 2 303 · Phase 3 54 · Phase 4 3
First in 1991; this study’s year is marked. 18 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 55 across the 550 interventional studies, 111 across the 51 observational. Of the 417 that completed or were terminated, 173 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
294 of 629 have an industry lead sponsor. The 10 most frequent:
This study is registered under G1 Therapeutics, Inc., one of the names counted as Pharmacosmos A/S. Under that name alone:
G1 Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Pharmacosmos A/S has 6 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
44 of the studies in Small Cell Lung Carcinoma with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01064466Phase 3Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms | 2026-11-18 |
| NCT06646276Phase 3Bristol-Myers SquibbA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | 2027-08-17 |
| NCT07778316Phase 3AmgenPhase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | 2027-09-24 |
| NCT04624204Phase 3Merck Sharp & Dohme LLCPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | 2027-10-28 |
| NCT07473128Phase 3Pharmacosmos A/SEffect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | 2027-10-31 |
Add all 44 to your calendar (.ics) → With an account.
Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC.
The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with study treatment and completes at the Post-Treatment Visit. Approximately, 90 patients will be enrolled in the study; 20 patients in the Part 1 and 70 patients in the Part 2 portion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
Drug: Carboplatin · Drug: Trilaciclib · Drug: Etoposide
All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
Drug: Carboplatin · Drug: Placebo · Drug: Trilaciclib · Drug: Etoposide
Also known as: Paraplatin
Also known as: G1T28
Also known as: VP-16, Toposar
Number of Participants With Dose Limiting Toxicities by Cohort in Cycle 1, Part 1
Dose-limiting toxicities (DLTs) were drug-related toxicities defined as follows: 1. Absolute neutrophil count (ANC) \< 0.5 × 10\^9/L lasting for ≥ 7 days 2. ≥ Grade 3 neutropenic infection/febrile neutropenia 3. Grade 4 thrombocytopenia (TCP) or ≥ Grade 3 TCP with bleeding 4. Unable to start next cycle of chemotherapy due to lack of recovery to an ANC ≥ 1.5 × 10\^9/L and platelet count ≥ 100 × 10\^9/L 5. ≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing maximal medical management; fatigue lasting for \> 72 hours) Toxicities not clearly related to etoposide/carboplatin therapy were also considered for the purposes of determining DLTs.
Time frame: Days 1-21 of Cycle 1
Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Related AEs, Related SAEs, and AEs Leading to Study Drug Discontinuation in Part 1
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. TEAEs were defined as any AE that started on or after the first dose of study drug and up to the last dose +30 days. SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. Relatedness to study drug was assessed by the investigator. Related refers to those events that were Possibly, Probably, or Definitely Related. AEs with an unknown/not reported onset date were also included.
Time frame: TEAEs were any AE that started on or after the first dose of study drug and up to the last dose +30 days (a minimum of 51 days up to a maximum of 374 days)
Duration of Severe (Grade 4) Neutropenia in Part 2
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Maximum Observed Plasma Concentration (Cmax) of Trilaciclib in Cycle 1, Part 1
Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle
Area Under the Plasma Concentration Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) for Trilaciclib in Cycle 1, Part 1
AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle
Time of Maximum Observed Concentration (Tmax) of Trilaciclib in Cycle 1, Part 1
Tmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle
Cmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
Cmax of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was BLQ was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Cmax values)
AUC0-inf of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
AUC0-inf of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 AUC0-inf values)
Tmax of Etoposide and Free and Total Carboplatin in Cycle 1, Part 1
Tmax of etoposide and free and total carboplatin in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
Time frame: Days 1 and 3 of Cycle 1 for a 21-day cycle (carboplatin was only dosed on Day 1 so there are no Day 3 Tmax values)
Duration of Severe (Grade 4) Neutropenia in Part 1
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Severe (Grade 4) Neutropenia in Part 1
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Febrile Neutropenia in Part 1
Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Duration of Grade 3/4 Neutropenia in Part 1
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Grade 3/4 Neutropenia in Part 1
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Nadir of Absolute Neutrophil Count in Cycle 1, Part 1
Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.
Time frame: From baseline to the end of Cycle 1
Occurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 1
Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) Version September 2017. A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Red Blood Cell (RBC) Transfusion in Part 1
Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 1
Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Occurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 1
Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Platelet Transfusion in Part 1
Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Change From Baseline of Platelet Count at the End of Cycle 6, Part 1
Blood samples were collected for local clinical laboratory assessment of platelet count.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1
Blood samples were collected for local clinical laboratory assessment of lymphocyte count.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Occurrence of Dose Reduction in Part 1
Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Infectious SAEs in Part 1
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Pulmonary Infection SAE in Part 1
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of IV Antibiotic Administration in Part 1
Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Time to First Major Adverse Hematologic Event (MAHE) in Part 1
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Best Overall Tumor Response Based on Assessments in Part 1
Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Overall visit response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was derived programmatically using data from target lesions (TLs), non-target lesions (NTLs), \& new lesions. Tumor response data were used to determine each participant's time point response \& best overall response (BOR). Complete response (CR) was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. Partial response (PR) was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for progressive disease (PD) were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. Stable disease (SD) was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% overall survival (OS) events observed (a maximum of 4 years)
Best Overall Tumor Response Based on Blinded Independent Central Review (BICR) Assessments in Part 1
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Progression Free Survival (PFS) Based on Assessments in Part 1
Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
OS in Part 1
OS was calculated as the time (months) from date of first dose of study drug for participants in Part 1 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.
Time frame: Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Occurrence of Severe (Grade 4) Neutropenia in Part 2
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Febrile Neutropenia in Part 2
Each febrile neutropenia event (as defined by CTCAE) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Duration of Grade 3/4 Neutropenia in Part 2
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Grade 3/4 Neutropenia in Part 2
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Nadir of Absolute Neutrophil Count in Cycle 1, Part 2
Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.
Time frame: From baseline to the end of Cycle 1
Occurrence of G-CSF Administration in Part 2
Administration of G-CSF was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where G-CSF was administered concurrently was identified bycomparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of RBC Transfusion in Part 2
Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions. If a participant did not have any RBC transfusions, they were assigned a value of 0.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Change From Baseline of Hemoglobin at the End of Cycle 6, Part 2
Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Occurrence of ESA Administration in Part 2
Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Platelet Transfusion in Part 2
Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Change From Baseline of Platelet Count at the End of Cycle 6, Part 2
Blood samples were collected for local clinical laboratory assessment of platelet count.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2
Blood samples were collected for local clinical laboratory assessment of lymphocyte count.
Time frame: Baseline, Day 1, Day 3, Day 8, Day 10, and Day 15 of a 21-day cycle x 6
Occurrence of Dose Reduction in Part 2
Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Infectious SAEs in Part 2
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of Pulmonary Infection SAE in Part 2
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Occurrence of IV Antibiotic Administration in Part 2
Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Time to First MAHE in Part 2
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.
Time frame: From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)
Best Overall Tumor Response Based on Assessments in Part 2
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was derived programmatically using data from TLs, NTLs, \& new lesions. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
Best Overall Tumor Response Based on BICR Assessments in Part 2
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
PFS Based on Assessments in Part 2
Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.
Time frame: Baseline, end of every two 21-day cycles, up until disease progression to a maximum of the time at least 70% OS events observed (a maximum of 4 years)
OS in Part 2
OS was calculated as the time (months) from date of first dose of study drug for participants in Part 2 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.
Time frame: Baseline up until death or a maximum of the time at least 70% OS events observed (a maximum of 4 years)
The study was conducted at 71 centers in the United States of America and Europe. The first participant enrolled on 26 June 2015 and the last participant completed on 22 February 2019. For Part 1, participants were enrolled from 26 June 2015 to 30 September 2016 and for Part 2, participants were enrolled from 06 October 2016 to 25 April 2017.
| Milestone | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P |
|---|---|---|
| Started | 19 | 77 |
| Completed | 0 | 0 |
| Not completed | 19 | 77 |
| Withdrew: Death | 17 | 56 |
| Withdrew: Study completion | 1 | 10 |
| Withdrew: Withdrawal by subject | 0 | 7 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Subject declined further treatment | 1 | 0 |
| Withdrew: Withdrawn by pi for compassionate reason | 0 | 1 |
| Withdrew: Randomized but not enrolled | 0 | 1 |
Dose-limiting toxicities (DLTs) were drug-related toxicities defined as follows: 1. Absolute neutrophil count (ANC) \< 0.5 × 10\^9/L lasting for ≥ 7 days 2. ≥ Grade 3 neutropenic infection/febrile neutropenia 3. Grade 4 thrombocytopenia (TCP) or ≥ Grade 3 TCP with bleeding 4. Unable to start next cycle of chemotherapy due to lack of recovery to an ANC ≥ 1.5 × 10\^9/L and platelet count ≥ 100 × 10\^9/L 5. ≥ Grade 3 nonhematologic toxicity (nausea, vomiting, and diarrhea failing maximal medical management; fatigue lasting for \> 72 hours) Toxicities not clearly related to etoposide/carboplatin therapy were also considered for the purposes of determining DLTs.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Number of participants meeting ≥1 DLT criteria | 2 | 1 |
| Grade 4 TCP or ≥Grade 3 TCP with bleeding | 1 | 0 |
| Unable to start next cycle of chemotherapy | 1 | 1 |
An AE was defined as any untoward medical occurrence in a participant administered a medicinal product that did not necessarily have a causal relationship with this treatment. TEAEs were defined as any AE that started on or after the first dose of study drug and up to the last dose +30 days. SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. Relatedness to study drug was assessed by the investigator. Related refers to those events that were Possibly, Probably, or Definitely Related. AEs with an unknown/not reported onset date were also included.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Any TEAE | 12 | 8 |
| Any SAE | 4 | 1 |
| TEAE related to any study drug | 10 | 8 |
| SAE related to any study drug | 0 | 0 |
| TEAE leading to discontinuation of any study drug | 0 | 0 |
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.
| Days | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Duration of Severe (Grade 4) Neutropenia in Part 2 | 8 (7 to 8) | 3 (2 to 3) |
Cmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was below the limit of quantification (BLQ) was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.
| ng/mL | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Day 1 Cycle 1 | 1240 ± 738 | 1570 ± NA |
| Day 3 Cycle 1 | 1620 ± 1040 | 2260 ± NA |
AUC0-inf of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
| h*ng/mL | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Day 1 Cycle 1 | 2560 ± 792 | 2280 ± NA |
| Day 3 Cycle 1 | 3110 ± 693 | 2960 ± NA |
Tmax of trilaciclib in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
| Hours | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Day 1 Cycle 1 | 0.57 (0.45 to 0.98) | 0.50 (NA to NA) |
| Day 3 Cycle 1 | 0.52 (0.47 to 1.00) | 0.45 (NA to NA) |
Cmax of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used. For estimation of Cmax, a concentration that was BLQ was assigned a value of zero if it occurred in a profile before the first measurable concentration. If a BLQ value occurred after a measurable concentration in a profile, and was followed by a value above the lower limit of quantification, then the BLQ was treated as missing data. If a BLQ value occurred at the end of the collection interval (after the last quantifiable concentration) it was treated as missing data. If two BLQ values occurred in succession after Cmax, the profile was deemed to have terminated at the first BLQ value and any subsequent concentrations were omitted.
| μg/mL | Part 1: Dose Finding/Expansion |
|---|---|
| Etoposide Day 1 Cycle 1 | 21.9 ± 2.70 |
| Etoposide Day 3 Cycle 1 | 20.2 ± 2.40 |
| Free Carboplatin Day 1 Cycle 1 | 20.3 ± 6.83 |
| Total Carboplatin Day 1 Cycle 1 | 18.8 ± 5.45 |
AUC0-inf of etoposide and free and total carboplatin in plasma were determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
| h*μg/mL | Part 1: Dose Finding/Expansion |
|---|---|
| Etoposide Day 1 Cycle 1 | 131 ± 44.7 |
| Etoposide Day 3 Cycle 1 | 146 ± 48.4 |
| Free Carboplatin Day 1 Cycle 1 | 50.5 ± 14.4 |
| Total Carboplatin Day 1 Cycle 1 | 137 ± 37.3 |
Tmax of etoposide and free and total carboplatin in plasma was determined from individual concentration-time data by non-compartmental analysis methods. The actual sampling times in relation to dosing were used.
| Hours | Part 1: Dose Finding/Expansion |
|---|---|
| Etoposide Day 1 Cycle 1 | 1.08 (0.90 to 2.67) |
| Etoposide Day 3 Cycle 1 | 1.00 (0.85 to 1.52) |
| Free Carboplatin Day 1 Cycle 1 | 0.52 (0.47 to 0.67) |
| Total Carboplatin Day 1 Cycle 1 | 0.52 (0.47 to 0.67) |
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. Within each cycle, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia only included participants who had at least 1 severe neutropenia event in the cycle, and censoring rules were applied for unresolved severe neutropenia in a cycle. For the treatment period, the overall duration of severe neutropenia was the median value among the durations from all cycles.
| Days | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Duration of Severe (Grade 4) Neutropenia in Part 1 | 6 (6 to 7) | — |
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Severe (Grade 4) Neutropenia in Part 1 | 4 | 0 |
Each febrile neutropenia event (as defined by Common Terminology Criteria for Adverse Events \[CTCAE\]) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Febrile Neutropenia in Part 1 | 0 | 0 |
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.
| Days | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Duration of Grade 3/4 Neutropenia in Part 1 | 8 (6 to 10) | 8 (5 to 9) |
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Grade 3/4 Neutropenia in Part 1 | 6 | 3 |
Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.
| x 10^9 cells/L | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Nadir of Absolute Neutrophil Count in Cycle 1, Part 1 | 1.198 ± 0.7241 | 1.653 ± 0.7381 |
Administration of G-CSF was collected with concomitant medications, which were coded using World Health Organization Drug Dictionary (WHO-DD) Version September 2017. A cycle where G-CSF was administered concurrently was identified by comparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Granulocyte-Colony Stimulating Factor (G-CSF) Administration in Part 1 | 5 | 3 |
Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Red Blood Cell (RBC) Transfusion in Part 1 | 4 | 1 |
Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.
| g/L | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Change From Baseline of Hemoglobin at the End of Cycle 6, Part 1 | -9.8 ± 13.27 | -20.1 ± 15.21 |
Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Erythropoietin Stimulating Agent (ESA) Administration in Part 1 | 2 | 0 |
Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Platelet Transfusion in Part 1 | 1 | 0 |
Blood samples were collected for local clinical laboratory assessment of platelet count.
| x 10^9 cells/L | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Change From Baseline of Platelet Count at the End of Cycle 6, Part 1 | -72.6 ± 88.38 | -59.4 ± 108.47 |
Blood samples were collected for local clinical laboratory assessment of lymphocyte count.
| x 10^9 cells/L | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 1 | 0.188 ± 0.8431 | 0.067 ± 0.4691 |
Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Dose Reduction in Part 1 | 2 | 3 |
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the Medical Dictionary for Regulatory Activities (MedDRA) system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Infectious SAEs in Part 1 | 2 | 1 |
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of Pulmonary Infection SAE in Part 1 | 1 | 0 |
Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Occurrence of IV Antibiotic Administration in Part 1 | 4 | 1 |
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.
| Months | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Time to First Major Adverse Hematologic Event (MAHE) in Part 1 | 2.6 (0.8 to NA) | 3.0 (1.0 to NA) |
Tumor response was assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Overall visit response by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was derived programmatically using data from target lesions (TLs), non-target lesions (NTLs), \& new lesions. Tumor response data were used to determine each participant's time point response \& best overall response (BOR). Complete response (CR) was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. Partial response (PR) was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for progressive disease (PD) were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. Stable disease (SD) was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| CR | 0 | 1 |
| PR | 8 | 7 |
| SD | 0 | 0 |
| PD | 1 | 0 |
| Not evaluable | 0 | 0 |
| Unconfirmed CR | 1 | 0 |
| Unconfirmed PR | 0 | 0 |
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| CR | 1 | 0 |
| PR | 6 | 8 |
| SD | 2 | 0 |
| PD | 0 | 0 |
| Not evaluable | 0 | 0 |
| Unconfirmed CR | 0 | 0 |
| Unconfirmed PR | 2 | 0 |
Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.
| Months | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| Progression Free Survival (PFS) Based on Assessments in Part 1 | 5.3 (1.5 to 6.1) | 6.3 (5.9 to 9.1) |
OS was calculated as the time (months) from date of first dose of study drug for participants in Part 1 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.
| Months | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 |
|---|---|---|
| OS in Part 1 | 10.6 (4.9 to 25.1) | 12.8 (9.5 to 13.5) |
Severe (Grade 4) neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Severe (Grade 4) Neutropenia in Part 2 | 16 | 2 |
Each febrile neutropenia event (as defined by CTCAE) was captured as an AE. The occurrence of febrile neutropenia was defined as at least 1 febrile neutropenia event during the treatment period. For the treatment period, the total number of febrile neutropenia events was the number of febrile neutropenia events with a unique start date.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Febrile Neutropenia in Part 2 | 3 | 1 |
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period. Within each cycle, duration (days) of Grade 3/4 neutropenia was defined as the number of days from the date of the first ANC value of \<1.0 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥1.0 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<1.0 × 10\^9/L and 2) no other ANC values \<1.0 × 10\^9/L occurred between this day and end of cycle. The duration of Grade 3/4 neutropenia only included participants who had at least 1 Grade 3/4 neutropenia event in the cycle, and censoring rules were applied for unresolved Grade 3/4 neutropenia in a cycle. For the treatment period, the overall duration of Grade 3/4 neutropenia was the median value among the durations of Grade 3/4 neutropenia from all cycles.
| Days | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Duration of Grade 3/4 Neutropenia in Part 2 | 8 (7 to 13) | 8 (6 to 8) |
Grade 3/4 neutropenia was defined as at least 1 ANC value \<1.0 × 10\^9/L during the treatment period.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Grade 3/4 Neutropenia in Part 2 | 30 | 14 |
Cycle nadir was the lowest value for ANC that occurred between start of cycle and end of cycle and was less than the cycle baseline.
| x 10^9 cells/L | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Nadir of Absolute Neutrophil Count in Cycle 1, Part 2 | 0.815 ± 0.6385 | 1.899 ± 1.1930 |
Administration of G-CSF was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where G-CSF was administered concurrently was identified bycomparing the start and stop dates of each administration of G-CSF to the start of cycle and end of cycle. The occurrence of G-CSF administrations was defined as at least 1 cycle with G-CSF administrations during the treatment period. For the treatment period, the total number of G-CSF administrations was the number of cycles with G-CSF administrations.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of G-CSF Administration in Part 2 | 24 | 4 |
Within a cycle, a RBC transfusion event was defined as either 1) an actual RBC transfusion, or 2) eligible for RBC transfusion (defined as hemoglobin \<8.0 g/dL). The occurrence of RBC transfusions was defined as at least 1 cycle with RBC transfusion during the treatment period. For the treatment period, the total number of RBC transfusions was the number of cycles with RBC transfusions. If a participant did not have any RBC transfusions, they were assigned a value of 0.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Overall | 9 | 6 |
| On/after Week 5 | 9 | 2 |
Blood samples were collected for local clinical laboratory assessment of hemoglobin levels.
| g/L | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Change From Baseline of Hemoglobin at the End of Cycle 6, Part 2 | -25.9 ± 14.63 | -20.6 ± 13.83 |
Administration of ESAs was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where an ESA was administered concurrently was identified by comparing the start and stop dates of each administration of an ESA to the start of cycle and end of cycle. The occurrence of ESA administration was at least 1 cycle with an ESA administration during the treatment period. For the treatment period, the total number of ESA administrations was the number of cycles with ESA administrations.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of ESA Administration in Part 2 | 2 | 1 |
Within a cycle, a platelet transfusion event was defined as either 1) an actual platelet transfusion, or 2) eligible for platelet transfusion (defined as a platelet count ≤10 × 10\^9/L). The occurrence of platelet transfusions was defined as at least 1 cycle with platelet transfusion during the treatment period. For the treatment period, the total number of platelet transfusions was the number of cycles with platelet transfusions.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Platelet Transfusion in Part 2 | 0 | 2 |
Blood samples were collected for local clinical laboratory assessment of platelet count.
| x 10^9 cells/L | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Change From Baseline of Platelet Count at the End of Cycle 6, Part 2 | -32.7 ± 100.20 | -54.4 ± 95.44 |
Blood samples were collected for local clinical laboratory assessment of lymphocyte count.
| x 10^9 cells/L | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Change From Baseline of Lymphocyte Count at the End of Cycle 6, Part 2 | -0.203 ± 0.4382 | 0.104 ± 0.6320 |
Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Dose Reduction in Part 2 | 13 | 3 |
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. An infectious SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of anal abscess, bacteraemia, bronchitis, candida infection, chronic sinusitis, conjunctivitis, infection, influenza, nasopharyngitis, oral candidiasis, oral herpes, pharyngitis streptococcal, pneumonia, pneumonia bacterial, respiratory tract infection, sepsis, skin infection, upper respiratory tract infection, urinary tract infection, urosepsis or viral upper respiratory tract infection.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Infectious SAEs in Part 2 | 2 | 4 |
SAEs were defined as any untoward medical occurrence that at any dose resulted in death, was life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect. A pulmonary infection SAE was a serious event in the MedDRA system organ class "infections and infestations" and a preferred term of bronchitis, influenza, pneumonia, pneumonia bacterial, respiratory tract infection, upper respiratory tract infection or viral upper respiratory tract infection.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of Pulmonary Infection SAE in Part 2 | 1 | 4 |
Intravenous antibiotic administration was collected with concomitant medications, which were coded using WHO-DD Version September 2017. A cycle where IV antibiotic was administered concurrently was identified by comparing the start and stop dates of each administration of IV antibiotic to the start of cycle and end of cycle. The occurrence of IV antibiotic administration was defined as at least 1 cycle with IV antibiotic administration during the treatment period. For the treatment period, the total number of IV antibiotic administrations was the number of cycles with IV antibiotic administrations.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Occurrence of IV Antibiotic Administration in Part 2 | 8 | 8 |
MAHE was a composite endpoint incorporating the measurement of several clinically meaningful aspects of myelopreservation into a single endpoint. The individual components for MAHE were hospitalization for a hematologic event, febrile neutropenia, death related to treatment, dose delay/reduction due to ANC or platelet counts, prolonged severe neutropenia (duration \>5 days), RBC transfusion (actual or eligible) and platelet transfusion (actual or eligible). Time to first occurrence of a MAHE event was defined as the first time to observe an interested event among all the components, starting from the first dose date of study drug administration.
| Months | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Time to First MAHE in Part 2 | 1.0 (0.5 to 2.3) | NA (3.3 to NA) |
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was derived programmatically using data from TLs, NTLs, \& new lesions. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| CR | 1 | 0 |
| PR | 19 | 24 |
| SD | 12 | 9 |
| PD | 4 | 1 |
| Not evaluable | 1 | 0 |
| Unconfirmed CR | 0 | 0 |
| Unconfirmed PR | 6 | 4 |
Tumor response was assessed by CT or MRI. Overall visit response by RECIST v1.1 was determined by BICR. Tumor response data were used to determine each participant's time point response \& BOR. CR was disappearance of all TLs, any pathological lymph nodes selected as TLs must have reduced in short axis to \<10 mm. PR was at least a 30% decrease from baseline in the sum of diameters of TLs, as long as criteria for PD were not met. PD was a ≥20% increase in the smallest sum of diameters of TLs since treatment started (including baseline) and an absolute increase of ≥5 mm. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| CR | 0 | 1 |
| PR | 23 | 23 |
| SD | 10 | 7 |
| PD | 4 | 2 |
| Not evaluable | 0 | 1 |
| Unconfirmed CR | 0 | 0 |
| Unconfirmed PR | 5 | 4 |
Tumor response was assessed by CT or MRI. PFS was defined as the time (months) from date of first dose date of study drug for participants in Part 1 until date of documented disease progression or death due to any cause, whichever occurred first. More specifically, PFS was determined using all the assessment data up until the last evaluable visit prior to or on the date of i) disease progression as defined by RECIST 1.1 or by clinical criteria as determined by the investigator; or ii) withdrawal of consent; or iii) receiving subsequent anticancer therapy, whichever was earlier. For PFS determined using response data derived programmatically, either clinical progression or progression by RECIST (whichever came first) was considered. Median and inter-quartile range of PFS were calculated using the Kaplan-Meier method.
| Months | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| PFS Based on Assessments in Part 2 | 5.0 (3.2 to 6.8) | 6.1 (4.2 to 9.5) |
OS was calculated as the time (months) from date of first dose of study drug for participants in Part 2 to the date of death due to any cause. Participants who did not die during the study were censored at the date last known to be alive. Participants lacking data beyond the day of first dose of study drug had their survival time censored at day of first dose of study drug. OS was not censored if a participant received other anti-tumor treatments after the study drugs. Median and inter-quartile range of OS were calculated using the Kaplan-Meier method.
| Months | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| OS in Part 2 | 10.6 (6.9 to 16.9) | 10.9 (7.3 to 20.1) |
In addition to deriving severe (Grade 4) neutropenia using the method described for the primary endpoints, an approach was applied that accounted for participants who did not experience a severe neutropenia event in Cycle 1. For the post-hoc analysis, severe neutropenia was defined as at least 1 ANC value \<0.5 × 10\^9/L during the treatment period. In Cycle 1, the duration (days) of severe neutropenia was defined as the number of days from the date of the first ANC value of \<0.5 × 10\^9/L observed between start of cycle and end of cycle to the date of the first ANC value ≥0.5 × 10\^9/L that met the following criteria: 1) occurred after the ANC value of \<0.5 × 10\^9/L and 2) no other ANC values \<0.5 × 10\^9/L occurred between this day and end of cycle. The duration of severe neutropenia was set to 0 for participants who did not experience severe neutropenia in Cycle 1. Data from unscheduled visits and the actual assessment date (rather than visit date) were included in the derivation.
| Days | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|
| Duration of Severe (Grade 4) Neutropenia in Cycle 1 of Part 2 | 0 (0 to 13) | 0 (0 to 3) |
Collected over All AEs occurring from the first date of administration of trilaciclib or placebo + E/P therapy through and including 30 calendar days after the last administration of trilaciclib or placebo + E/P therapy were recorded (a minimum of 51 days up to a maximum of 374 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | 9/12 (75%) | 4/12 (33.3%) | 12/12 (100%) |
| Part 1: Cohort 2 Trilaciclib 240mg/m^2 | 8/8 (100%) | 1/8 (12.5%) | 8/8 (100%) |
| Part 2: Placebo | 28/37 (75.7%) | 9/37 (24.3%) | 36/37 (97.3%) |
| Part 2: Trilaciclib 240 mg/m^2 | 28/38 (73.7%) | 11/38 (28.9%) | 37/38 (97.4%) |
| Event | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|---|---|
| Cardiac failure chronicCardiac disorders | 0/12 | 1/8 | 0/37 | 0/38 |
| StomatitisGastrointestinal disorders | 0/12 | 1/8 | 0/37 | 0/38 |
| Oral candidiasisInfections and infestations | 0/12 | 1/8 | 0/37 | 0/38 |
| Myocardial infarctionCardiac disorders | 1/12 | 0/8 | 0/37 | 0/38 |
| Bone painMusculoskeletal and connective tissue disorders | 1/12 | 0/8 | 0/37 | 0/38 |
| PneumoniaInfections and infestations | 1/12 | 0/8 | 1/37 | 2/38 |
| UrosepsisInfections and infestations | 1/12 | 0/8 | 0/37 | 0/38 |
| AnemiaBlood and lymphatic system disorders | 0/12 | 0/8 | 2/37 | 0/38 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/12 | 0/8 | 1/37 | 2/38 |
| Deep vein thrombosisVascular disorders | 0/12 | 0/8 | 1/37 | 0/38 |
| Event | Part 1: Cohort 1 Trilaciclib 200 mg/m^2 | Part 1: Cohort 2 Trilaciclib 240mg/m^2 | Part 2: Placebo | Part 2: Trilaciclib 240 mg/m^2 |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 5/12 | 5/8 | 23/37 | 9/38 |
| FatigueGeneral disorders | 7/12 | 4/8 | 6/37 | 16/38 |
| NauseaGastrointestinal disorders | 5/12 | 4/8 | 8/37 | 13/38 |
| ConstipationGastrointestinal disorders | 4/12 | 4/8 | 8/37 | 9/38 |
| VomitingGastrointestinal disorders | 4/12 | 4/8 | 5/37 | 3/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/12 | 4/8 | 3/37 | 5/38 |
| DehydrationMetabolism and nutrition disorders | 1/12 | 4/8 | 1/37 | 0/38 |
| AnemiaBlood and lymphatic system disorders | 5/12 | 1/8 | 15/37 | 10/38 |
| LeukopeniaBlood and lymphatic system disorders | 5/12 | 0/8 | 5/37 | 2/38 |
| AlopeciaSkin and subcutaneous tissue disorders | 5/12 | 3/8 | 11/37 | 6/38 |
All participants randomized
| Age, Categorical(Participants) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 37 | 44 |
| >=65 years | 12 | 40 | 52 |
| Sex: Female, Male(Participants) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| Female | 8 | 23 | 31 |
| Male | 11 | 54 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 18 | 75 | 93 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 16 | 73 | 89 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Country(Participants) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| United States | 19 | 39 | 58 |
| Non-United States | 0 | 38 | 38 |
| Body Surface Area(m^2) | Part 1: Dose Finding/Expansion | Part 2: Trilaciclib/Placebo IV With E/P | Total |
|---|---|---|---|
| Mean | 1.90 ± 0.263 | 1.90 ± 0.216 | NA ± NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Jul 2017, 24 months.
Results were first posted in Jul 2020, 3 years after primary completion. A results delay was requested in Nov 2018.
Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's 24 months is below that.
Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trilaciclib